Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.

EP: 1.Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP: 2.Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP: 3.Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP: 4.ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP: 5.Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP: 6.Elacestrant: Treatment Considerations, Including Dosing and Compliance

EP: 7.Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP: 8.Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

EP: 9.Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer

EP: 10.Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer

EP: 11.The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

Now Viewing

EP: 12.Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

EP: 13.Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

Related Videos

Related Content

Advertisement

July 23rd 2025

Venetoclax Consolidation a Feasible Strategy After BTKi in CLL

Jared Kaltwasser

Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 21st 2025

Underuse of Maintenance Therapies Highlights Need for Improved Care Strategies in Advanced Ovarian Cancer

Brooke McCormick

Fewer than half of eligible patients with advanced ovarian cancer receive first-line maintenance treatments, highlighting care gaps.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 18th 2025

Semaglutide, Tirzepatide Cut Dementia, Stroke Risk in Type 2 Diabetes

Pearl Steinzor

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

July 16th 2025

Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL

Mary Caffrey

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).

Related Content

Advertisement

July 23rd 2025

Venetoclax Consolidation a Feasible Strategy After BTKi in CLL

Jared Kaltwasser

Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 21st 2025

Underuse of Maintenance Therapies Highlights Need for Improved Care Strategies in Advanced Ovarian Cancer

Brooke McCormick

Fewer than half of eligible patients with advanced ovarian cancer receive first-line maintenance treatments, highlighting care gaps.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 18th 2025

Semaglutide, Tirzepatide Cut Dementia, Stroke Risk in Type 2 Diabetes

Pearl Steinzor

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

July 16th 2025

Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL

Mary Caffrey

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).